{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:57:42Z","timestamp":1740128262382,"version":"3.37.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CARITRO","award":["CRP-59781","CRP-59781 fellowship"],"award-info":[{"award-number":["CRP-59781","CRP-59781 fellowship"]}]},{"name":"Regione Sardegna","award":["RAS LR-2012"],"award-info":[{"award-number":["RAS LR-2012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13365-016-0492-x","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T13:46:38Z","timestamp":1478180798000},"page":"226-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["JC polyomavirus expression and bell-shaped regulation of its SF2\/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab"],"prefix":"10.1007","volume":"23","author":[{"given":"Elena","family":"Uleri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Piu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giannina","family":"Arru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GianPietro","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-5310","authenticated-orcid":false,"given":"Antonina","family":"Dolei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"492_CR1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458513494957","volume":"20","author":"G Arru","year":"2014","unstructured":"Arru G, Leoni S, Pugliatti M, Mei A, Serra C, Delogu LG, Manetti R, Dolei A, Sotgiu S, Mameli G (2014) Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study. Mult Scler 20:174\u2013182","journal-title":"Mult Scler"},{"key":"492_CR2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/0042-6822(92)90909-9","volume":"190","author":"WJ Atwood","year":"1992","unstructured":"Atwood WJ, Amemiya K, Traub R, Harms J, Major EO (1992) Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology 190:716\u2013723","journal-title":"Virology"},{"key":"492_CR3","doi-asserted-by":"crossref","unstructured":"Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G (2016) Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler 22:1315\u20131326","DOI":"10.1177\/1352458516650736"},{"key":"492_CR4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","volume":"22","author":"JR Berger","year":"2016","unstructured":"Berger JR, Fox RJ (2016) Reassessing the risk of natalizumab-associated PML. J Neurovirol 22:533\u2013535","journal-title":"J Neurovirol"},{"key":"492_CR5","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyan M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of Natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"492_CR6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/13550289809114524","volume":"4","author":"R Boldorini","year":"1998","unstructured":"Boldorini R, Caldarelli-Stefano R, Monga G, Zocchi M, Mediati M, Tosoni A, Ferrante P (1998) PCR detection of JC virus DNA in the brain tissue of a 9-year-old child with pleomorphic xanthoastrocytoma. J Neurovirol 4:242\u2013245","journal-title":"J Neurovirol"},{"key":"492_CR7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cytogfr.2014.10.011","volume":"26","author":"MR Capobianchi","year":"2015","unstructured":"Capobianchi MR, Uleri E, Caglioti C, Dolei A (2015) Type I IFN family members: similarity, differences and interaction. Cytokine Growth Factor Rev 26:103\u2013111","journal-title":"Cytokine Growth Factor Rev"},{"key":"492_CR8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.24148","volume":"75","author":"S Chalkias","year":"2014","unstructured":"Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, Donnelly M, Ionete C, Houtchens MK, Buckle GJ, Batson S, Koralnik IJ (2014) JC virus reactivation during prolonged Natalizumab monotherapy for multiple sclerosis. Ann Neurol 75:925\u2013934","journal-title":"Ann Neurol"},{"key":"492_CR9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/653823","volume":"202","author":"ML Chapagain","year":"2010","unstructured":"Chapagain ML, Nerurkar VR (2010) Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 202:184\u2013191","journal-title":"J Infect Dis"},{"key":"492_CR10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/1352458514551456","volume":"21","author":"M Chiarini","year":"2015","unstructured":"Chiarini M, Sottini A, Bertoli D, Serana F, Caimi L, Rasia S, Capra R, Imberti L (2015) Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients. Mult Scler 21:726\u2013734","journal-title":"Mult Scler"},{"key":"492_CR11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod in multiple sclerosis. Clin Neuropharmacol 33:91\u2013101","journal-title":"Clin Neuropharmacol"},{"key":"492_CR12","doi-asserted-by":"crossref","first-page":"e111115","DOI":"10.1371\/journal.pone.0111115","volume":"9","author":"N Claes","year":"2014","unstructured":"Claes N, Dhaeze T, Fraussen J, Broux B, Van Wijmeersch B, Stinissen P, Hupperts R, Hellings N, Somers V (2014) Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS One 9:e111115","journal-title":"PLoS One"},{"key":"492_CR13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1586\/17512433.2015.1036030","volume":"8","author":"J Craddock","year":"2015","unstructured":"Craddock J, Markovic-Plese S (2015) Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing. Expert Rev Clin Pharmacol 8:283\u2013296","journal-title":"Expert Rev Clin Pharmacol"},{"key":"492_CR14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12985-015-0426-x","volume":"12","author":"M Craigie","year":"2015","unstructured":"Craigie M, Regan P, Otalora YL, Sariyer IK (2015) Molecular interplay between T-antigen and splicing factor, arginine\/serine-rich 1 (SRSF1) controls JC virus gene expression in glial cells. Virol J 12:196","journal-title":"Virol J"},{"key":"492_CR15","doi-asserted-by":"crossref","unstructured":"De Gascun CF, Carr MJ (2013) Human polyomavirus reactivation: disease pathogenesis and treatment approaches. Clin Dev Immunol 2013:373579","DOI":"10.1155\/2013\/373579"},{"key":"492_CR16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WCO.0000000000000321","volume":"29","author":"D Dubey","year":"2016","unstructured":"Dubey D, Cano CA, St\u00fcve O (2016) Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Curr Opin Neurol 29:278\u2013285","journal-title":"Curr Opin Neurol"},{"key":"492_CR17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1099\/0022-1317-79-4-789","volume":"79","author":"C Elsner","year":"1998","unstructured":"Elsner C, D\u00f6rries K (1998) Human polyomavirus JC control region variants in persistently infected CNS and kidney tissue. J Gen Virol 79:789\u2013799","journal-title":"J Gen Virol"},{"key":"492_CR18","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14740338.2015.1093620","volume":"14","author":"M Faulkner","year":"2015","unstructured":"Faulkner M (2015) Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opin Drug Saf 14:1737\u20131748","journal-title":"Expert Opin Drug Saf"},{"key":"492_CR19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","volume":"71","author":"EM Frohman","year":"2014","unstructured":"Frohman EM, Mc M, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO (2014) JC virus in CD34+ and Cd19+ cells in patients with multiple sclerosis treated with Natalizumab. JAMA Neurol 71:596\u2013602","journal-title":"JAMA Neurol"},{"key":"492_CR20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.0000000000002330","volume":"86","author":"MS Gagne Brosseau","year":"2016","unstructured":"Gagne Brosseau MS, Stobbe G, Wundes A (2016) Natalizumab-related PML 2\u00a0weeks after negative anti-JCV antibody assay. Neurology 86:484\u2013486","journal-title":"Neurology"},{"key":"492_CR21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1086\/653824","volume":"202","author":"SA Houff","year":"2010","unstructured":"Houff SA, Berger J (2010) The curious incident of the dog in the nighttime: does the absence of virus replication in Epstein-Barr virus-transformed B cells point to an important feature of JC virus biology? J Infect Dis 202:181\u2013183","journal-title":"J Infect Dis"},{"key":"492_CR22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM198802043180507","volume":"318","author":"SA Houff","year":"1988","unstructured":"Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, Roberts JR, Gitt J, Saini N, Lux W (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318:301\u2013305","journal-title":"N Engl J Med"},{"key":"492_CR23","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00415-012-6809-7","volume":"260","author":"L Kappos","year":"2013","unstructured":"Kappos L, O\u2019Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C (2013) Clinical effects of Natalizumab on multiple sclerosis appear early in treatment course. J Neurol 260:1388\u20131395","journal-title":"J Neurol"},{"key":"492_CR24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.24302","volume":"76","author":"IJ Koralnik","year":"2014","unstructured":"Koralnik IJ (2014) Finger pointing to JC virus: a tale of two indexes. Ann Neurol 76:789\u2013791","journal-title":"Ann Neurol"},{"key":"492_CR25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S20791","volume":"9","author":"B Kornek","year":"2015","unstructured":"Kornek B (2015) An update on the use of Natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence 9:675\u2013684","journal-title":"Patient Prefer Adherence"},{"key":"492_CR26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cei.12261","volume":"176","author":"T Koudriavtseva","year":"2014","unstructured":"Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D\u2019Agosto G, Cordiali-Fei P (2014) Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with Natalizumab. Clin Exp Immunol 176:320\u2013326","journal-title":"Clin Exp Immunol"},{"key":"492_CR27","doi-asserted-by":"crossref","unstructured":"Kowalski CJ (1972) On the effects of non-normality on the distribution of the sample product-moment correlation coefficient. J R Stat Soc Ser C Appl Stat 1\u201312","DOI":"10.2307\/2346598"},{"key":"492_CR28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","volume":"194","author":"RLP Lindberg","year":"2008","unstructured":"Lindberg RLP, Achtnichts L, Hoffman F, Kuhle J, Kappos L (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 194:153\u2013164","journal-title":"J Neuroimmunol"},{"key":"492_CR29","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMc1213681","volume":"369","author":"EO Major","year":"2013","unstructured":"Major EO, Frohman E, Douek D (2013) More on JC viremia in Natalizumab-treated patients with multiple sclerosis. N Engl J Med 369:1280","journal-title":"N Engl J Med"},{"issue":"2","key":"492_CR30","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3949\/ccjm.78.s2.02","volume":"78","author":"EO Major","year":"2011","unstructured":"Major EO (2011) History and current concepts in the pathogenesis of PML. Clev Clin J Med 78(2):S3\u2013S7","journal-title":"Clev Clin J Med"},{"key":"492_CR31","doi-asserted-by":"crossref","first-page":"e78474","DOI":"10.1371\/journal.pone.0078474","volume":"8","author":"G Mameli","year":"2013","unstructured":"Mameli G, Madeddu G, Mei A, Uleri E, Poddighe L, Delogu LG, Maida I, Babudieri S, Serra C, Manetti R, Mura MS, Dolei A (2013) Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis? PLoS One 8:e78474","journal-title":"PLoS One"},{"key":"492_CR32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1101\/gad.10.13.1569","volume":"10","author":"JL Manley","year":"1996","unstructured":"Manley JL, Tacke R (1996) SR proteins and splicing control. Genes Dev 10:1569\u20131579","journal-title":"Genes Dev"},{"key":"492_CR33","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1128\/JVI.03221-13","volume":"88","author":"LJ Marshall","year":"2014","unstructured":"Marshall LJ, Ferenczy MW, Daley EL, Jensen PN, Ryschkewitsch CF, Major EO (2014) Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol 88:5177\u20135183","journal-title":"J Virol"},{"key":"492_CR34","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1212\/NXI.0000000000000223","volume":"3","author":"M Meira","year":"2016","unstructured":"Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, D\u00e9card BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL (2016) Natalizumab-induced POU2AF1\/Spi-B upregulation: a possible route for PML development. Neurol Neuroimmunol Neuroinflamm 3:e223","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"492_CR35","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/JVI.70.10.7004-7012.1996","volume":"70","author":"MC Monaco","year":"1996","unstructured":"Monaco MC, Atwood WJ, Gravell M, Major EO (1996) JCV infection of hematopoietic progenitor cells, primary B lymphocytes and tonsillar stromal cells: implication for viral latency. J Virol 70:7004\u20137012","journal-title":"J Virol"},{"key":"492_CR36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2015.00159","volume":"6","author":"MC Monaco","year":"2015","unstructured":"Monaco MC, Major EO (2015) Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors. Front Immunol 6:159","journal-title":"Front Immunol"},{"key":"492_CR37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/infdis\/127.4.467","volume":"127","author":"BL Padgett","year":"1973","unstructured":"Padgett BL, Walker DL (1973) Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 127:467\u2013470","journal-title":"J Infect Dis"},{"key":"492_CR38","doi-asserted-by":"crossref","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","volume":"8","author":"MR Perkins","year":"2012","unstructured":"Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC (2012) Changes in JC virus-specific T cell responses during Natalizumab treatment and in Natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog 8:e1003014","journal-title":"PLoS Pathog"},{"key":"492_CR39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s13365-015-0338-y","volume":"21","author":"V Pietropaolo","year":"2015","unstructured":"Pietropaolo V, Bellizzi A, Anzivino E, Iannetta M, Zingaropoli MA, Rodio DM, Morreale M, Pontecorvo S, Francia A, Vullo V, Palamara AT, Ciardi MR (2015) Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under Natalizumab treatment. J Neurovirol 21:653\u2013665","journal-title":"J Neurovirol"},{"key":"492_CR40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812","journal-title":"Ann Neurol"},{"key":"492_CR41","doi-asserted-by":"crossref","first-page":"e14630","DOI":"10.1371\/journal.pone.0014630","volume":"6","author":"IK Sariyer","year":"2011","unstructured":"Sariyer IK, Khalili K (2011) Regulation of human neurotropic JC virus replication by alternative splicing factor SF2\/ASF in glial cells. PLoS One 6:e14630","journal-title":"PLoS One"},{"key":"492_CR42","doi-asserted-by":"crossref","first-page":"e0156819","DOI":"10.1371\/journal.pone.0156819","volume":"11","author":"IK Sariyer","year":"2016","unstructured":"Sariyer IK, Sariyer R, Otte J, Gordon J (2016a) Pur-alpha induces JCV gene expression and viral replication by suppressing SRSF1 in glial cells. PLoS One 11:e0156819","journal-title":"PLoS One"},{"key":"492_CR43","doi-asserted-by":"crossref","unstructured":"Sariyer R, De Simone FI, Gordon J, Sariyer IK (2016b). Immune suppression of JC virus gene expression is mediated by SRSF1. J Neurovirol 22:597\u2013606","DOI":"10.1007\/s13365-016-0432-9"},{"key":"492_CR44","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/archneurol.2011.238","volume":"68","author":"C Saure","year":"2011","unstructured":"Saure C, Warnke C, Zohren F, Schroeder T, Bruns I, Cadeddu RP, Weigelt C, Fischer U, Kobbe G, Hartung HP, Adams O, Kieseier BC, Haas R (2011) Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 68:1428\u20131431","journal-title":"Arch Neurol"},{"key":"492_CR45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/aid.2007.0198","volume":"24","author":"C Serra","year":"2008","unstructured":"Serra C, Biolchini A, Mei A, Kotenko S, Dolei A (2008) Type III and I interferons increase HIV uptake and replication in human cells that overexpress CD4, CCR5, and CXCR4. AIDS Res Hum Retrovir 24:173\u2013180","journal-title":"AIDS Res Hum Retrovir"},{"key":"492_CR46","doi-asserted-by":"crossref","unstructured":"Shimoni-Sebag A, Lebenthal-Loinger I, Zender L, Karni R (2013) RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation. Carcinogenesis 34:2498\u20132504","DOI":"10.1093\/carcin\/bgt247"},{"key":"492_CR47","doi-asserted-by":"crossref","unstructured":"Sinha R, Allemand E, Zhang Z, Karni R, Myers MP, Krainer AR (2010) Arginine methylation controls the subcellular localization and functions of the oncoprotein splicing factor SF2\/ASF. Mol Cell Biol 30:2762\u20132774","DOI":"10.1128\/MCB.01270-09"},{"key":"492_CR48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1086\/597117","volume":"199","author":"CS Tan","year":"2009","unstructured":"Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller J, Koralnik IJ (2009) Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 199:881\u2013888","journal-title":"J Infect Dis"},{"key":"492_CR49","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1177\/1947601911424578","volume":"2","author":"E Uleri","year":"2011","unstructured":"Uleri E, Beltrami S, Gordon J, Dolei A, Sariyer IK (2011) Extinction of tumor antigen expression by SF2\/ASF in JCV-transformed cells. Genes Cancer 2:728\u2013736","journal-title":"Genes Cancer"},{"key":"492_CR50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1743-422X-10-147","volume":"10","author":"E Uleri","year":"2013","unstructured":"Uleri E, Regan P, Dolei A, Sariyer IK (2013) SF2\/ASF binding region within JC virus NCCR limits early gene transcription in glial cells. Virol J 10:147","journal-title":"Virol J"},{"key":"492_CR51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"492_CR52","doi-asserted-by":"crossref","unstructured":"Van Schependom J, Gielen J, Laton J, Nagels G (2015) Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail. Mult Scler 22:389\u2013392","DOI":"10.1177\/1352458515596458"},{"key":"492_CR53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/cid\/cir507","volume":"53","author":"RP Viscidi","year":"2011","unstructured":"Viscidi RP, Khanna N, Tan CS, Li X, Jacobson L, Clifford DB, Nath A, Margolick JB, Shah KV, Hirsch HH, Koralnik IJ (2011) JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 53:711\u2013715","journal-title":"Clin Infect Dis"},{"key":"492_CR54","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1586\/14737175.2015.1102061","volume":"15","author":"G Vitaliti","year":"2015","unstructured":"Vitaliti G, Matin N, Tabatabaie O, Di Traglia M, Pavone P, Lubrano R, Falsaperla R (2015) Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children. Expert Rev Neurother 15:1321\u20131341","journal-title":"Expert Rev Neurother"},{"key":"492_CR55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1352458510385834","volume":"17","author":"C Warnke","year":"2011","unstructured":"Warnke C, Smolianov V, Dehmel T, Andr\u00e9e M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC (2011) CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 17:151\u2013156","journal-title":"Mult Scler"},{"key":"492_CR56","doi-asserted-by":"crossref","unstructured":"Wei G, Liu CK, Atwood WJ (2000) JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol 6:127\u2013136","DOI":"10.3109\/13550280009013156"},{"key":"492_CR57","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiq097","volume":"203","author":"MK White","year":"2011","unstructured":"White MK, Khalili K (2011) Pathogenesis of progressive multifocal leukoencephalopathy-revisited. J Infect Dis 203:578\u2013586","journal-title":"J Infect Dis"},{"key":"492_CR58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/rmv.1866","volume":"26","author":"MK White","year":"2016","unstructured":"White MK, Sariyer IK, Gordon J, Delbue S, Pietropaolo V, Berger JR, Khalili K (2016) Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy. Rev Med Virol 26:102\u2013114","journal-title":"Rev Med Virol"},{"key":"492_CR59","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bmt.2015.68","volume":"50","author":"T Wittmann","year":"2015","unstructured":"Wittmann T, Horowitz N, Benyamini N, Henig I, Zuckerman T, Rowe JM, Kra-Oz Z, Szwarcwort Cohen M, Oren I, Avivi I (2015) JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications. Bone Marrow Transplant 50:984\u2013991","journal-title":"Bone Marrow Transplant"},{"key":"492_CR60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1570162X1401151102125319","volume":"14","author":"HS Wollebo","year":"2016","unstructured":"Wollebo HS, Cotto B, Adiga R, Langford D, White MK (2016) Expression of signaling molecules in progressive multifocal leukoencephalopathy. Curr HIV Res 14:47\u201353","journal-title":"Curr HIV Res"},{"key":"492_CR61","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","volume":"77","author":"HS Wollebo","year":"2015","unstructured":"Wollebo HS, White MK, Gordon J, Berger JR, Khalili K (2015) Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560\u2013570","journal-title":"Ann Neurol"},{"key":"492_CR62","doi-asserted-by":"crossref","unstructured":"Zhao Y, Zhu T, Zhang X, Wang Q, Zhang J, Ji W, Ma Y (2015) Splicing factor 2\/alternative splicing factor contributes to extracellular signal-regulated kinase activation in hepatocellular carcinoma cells. Mol Med Rep 12:3890\u20133894","DOI":"10.3892\/mmr.2015.3851"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-016-0492-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:30:07Z","timestamp":1601177407000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-016-0492-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1007\/s13365-016-0492-x","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"type":"print","value":"1355-0284"},{"type":"electronic","value":"1538-2443"}],"subject":[],"published":{"date-parts":[[2016,11,3]]}}}